Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 8, Pages e003132
Publisher
BMJ
Online
2021-08-28
DOI
10.1136/jitc-2021-003132
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
- (2020) Qianqian Ni et al. Science Advances
- The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
- (2020) Nathalie Percie du Sert et al. BRITISH JOURNAL OF PHARMACOLOGY
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of PD-1 Blockade in Cancer Immunotherapy
- (2019) Xiaomo Wu et al. Computational and Structural Biotechnology Journal
- Macrophages and hepatocellular carcinoma
- (2019) Zhiqiang Tian et al. Cell and Bioscience
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of STAT3 in leading the crosstalk between human cancers and the immune system
- (2018) Yu Wang et al. CANCER LETTERS
- SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin–Rho GTPase–Hippo Pathways
- (2018) Yan-Li Zhang et al. CANCER RESEARCH
- Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
- (2018) Tao Shi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- The Cancer Immunotherapy Revolution
- (2018) Priscilla N. Kelly SCIENCE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Programming CAR-T cells to kill cancer
- (2018) Louai Labanieh et al. Nature Biomedical Engineering
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Nanoengineering of vaccines using natural polysaccharides
- (2015) Ana Sara Cordeiro et al. BIOTECHNOLOGY ADVANCES
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
- (2015) Cyrille J. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Colorectal cancer
- (2015) Ernst J. Kuipers et al. Nature Reviews Disease Primers
- Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells
- (2014) Moonkyu Lee et al. ARCHIVES OF PHARMACAL RESEARCH
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
- (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group) LANCET
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Size-Dependent Uptake of Particles by Pulmonary Antigen-Presenting Cell Populations and Trafficking to Regional Lymph Nodes
- (2013) Fabian Blank et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
- (2011) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines
- (2011) Lijin Li et al. Cancers
- Intracellular Toll-like Receptors
- (2010) Amanda L. Blasius et al. IMMUNITY
- Sipuleucel-T
- (2010) Celestia S. Higano et al. NATURE REVIEWS DRUG DISCOVERY
- Randomized Phase II Trial Evaluating Two Paclitaxel and Cisplatin–Containing Chemoradiation Regimens As Adjuvant Therapy in Resected Gastric Cancer (RTOG-0114)
- (2009) Gary K. Schwartz et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now